AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33743477 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia exposure in patients <7 years at diagnosis
Number of subjects: 107
Study 33743477 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia exposure in patients ≥7 years at diagnosis
Number of subjects: 107
Study 33743477 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia exposure in high-risk disease patients
Number of subjects: 107
Study 33743477 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia exposure in average-risk disease patients
Number of subjects: 107
Study 33743541 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral therapy (cART) for HBV-HIV co-infection
Number of subjects: 139
Study 33743588 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ≥1 respiratory depression episode
Number of subjects: 1335
Study 33743588 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk patients with ≥1 respiratory depression episode
Number of subjects: 1335
Study 33743588 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 1335
Study 33743644 — intervention group
Group type: EXPERIMENTAL
Intervention: m-VISTA technique
Number of subjects: 10
Study 33743786 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-facing family health history risk assessment platform
Number of subjects: 102
Study 33743801 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose vitamin D3 (400 IU daily for 24 weeks)
Number of subjects: 50
Study 33743801 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose vitamin D3 (3200 IU daily for 12 weeks then 800 IU daily for 12 weeks)
Number of subjects: 50
Study 33743801 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical monitoring (25-hydroxyvitamin D, corrected calcium, albumin, parathyroid hormone, hepcidin, other vitamin D metabolites, iron studies, C-reactive protein)
Number of subjects: 50
Study 33743801 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal calprotectin measurement
Number of subjects: 50
Study 33743804 — intervention group
Group type: EXPERIMENTAL
Intervention: TEMPO (10-week, interactive, web-based intervention)
Number of subjects: 40
Study 33743804 — intervention group
Group type: EXPERIMENTAL
Intervention: TEMPO
Number of subjects: 40
Study 33743804 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 33744039 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma LA (linoleic acid) levels
Number of subjects: 2329
Study 33744114 — intervention group
Group type: EXPERIMENTAL
Intervention: KDIGO urine output criteria for AKI
Number of subjects: 141
Study 33744114 — intervention group
Group type: COMPARATOR
Intervention: KDIGO creatinine criteria for AKI
Number of subjects: 141
Study 33744114 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI stage assessed by urine output
Number of subjects: 141
Study 33744150 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Tricuspid Repair
Number of subjects: 0
Study 33744169 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional fecal microbiota transfer (bFMT)
Number of subjects: 0
Study 33744169 — intervention group
Group type: COMPARATOR
Intervention: Standard routes of application (LGIT, UGIT, CAP)
Number of subjects: 0
Study 33744468 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SAS)
Number of subjects: 0
Study 33744468 — intervention group
Group type: COMPARATOR
Intervention: Anti-PD-1/PD-L1 therapy
Number of subjects: 0
Study 33745032 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CHK1 inhibitor prexasertib (105 mg/m2) and anti-PD-L1 antibody LY3300054
Number of subjects: 17
Study 33745032 — intervention group
Group type: COMPARATOR
Intervention: Anti-PD-L1 antibody LY3300054 (Arm A)
Number of subjects: 17
Study 33745032 — intervention group
Group type: COMPARATOR
Intervention: CHK1 inhibitor prexasertib (Arm B)
Number of subjects: 17
Study 33745213 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacroiliac joint (SIJ) belt application
Number of subjects: 63
Study 33745213 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacroiliac joint (SIJ) belt after 4 weeks
Number of subjects: 63
Study 33745293 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention for ASD
Number of subjects: 63
Study 33745293 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention for VSD
Number of subjects: 63
Study 33745293 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 63
Study 33745499 — intervention group
Group type: EXPERIMENTAL
Intervention: FFQ (Food Frequency Questionnaire)
Number of subjects: 1007
Study 33745499 — intervention group
Group type: COMPARATOR
Intervention: 3DFD (3-day Food Diary)
Number of subjects: 1007
Study 33745602 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink consumption by non-habitual caffeine consumers
Number of subjects: 48
Study 33745602 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink consumption by habitual caffeine consumers
Number of subjects: 48
Study 33745602 — intervention group
Group type: COMPARATOR
Intervention: Control group (high-habitual caffeine consumers)
Number of subjects: 48
Study 33745805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 3708
Study 33745805 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 3708
Study 33746047 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent cytotoxic chemotherapy
Number of subjects: 4966
Study 33746047 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific anticancer therapies (e.g. R-CHOP, platinum combined with etoposide, DNA methyltransferase inhibitors)
Number of subjects: 4966
Study 33746047 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, male sex, obesity, cardiovascular and pulmonary comorbidities, renal disease, diabetes mellitus, non-Hispanic black race, Hispanic ethnicity, worse Eastern Cooperative Oncology Group performance status
Number of subjects: 4966
Study 33746047 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory measurements (low/high absolute lymphocyte count, high absolute neutrophil count, low platelet count, abnormal creatinine, troponin, lactate dehydrogenase, C-reactive protein)
Number of subjects: 4966
Study 33746047 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis early in the COVID-19 pandemic (January-April 2020)
Number of subjects: 4966
Study 33746446 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Image Analysis (DIA)
Number of subjects: 50
Study 33746446 — intervention group
Group type: COMPARATOR
Intervention: Conventional Cytological Evaluation (CCE)
Number of subjects: 50
Study 33746446 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both DIA and CCE
Number of subjects: 50
Study 33746446 — intervention group
Group type: EXPERIMENTAL
Intervention: DIA alone
Number of subjects: 50
Study 33746446 — intervention group
Group type: COMPARATOR
Intervention: CCE alone
Number of subjects: 50
Study 33746446 — intervention group
Group type: EXPERIMENTAL
Intervention: DIA and CCE together
Number of subjects: 50
Study 33746446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis of DIA
Number of subjects: 50
Study 33746576 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal Phase Ovarian Stimulation
Number of subjects: 0
Study 33746576 — intervention group
Group type: COMPARATOR
Intervention: Follicular Phase Ovarian Stimulation
Number of subjects: 0
Study 33746639 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter closure of mitral PVL
Number of subjects: 35
Study 33746830 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation techniques
Number of subjects: 0
Study 33746830 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33746857 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular Approach to Therapy for Children (MATCH)
Number of subjects: 0
Study 33746857 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33747081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCA)
Number of subjects: 30
Study 33747081 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 30
Study 33747081 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy
Number of subjects: 30
Study 33748052 — intervention group
Group type: EXPERIMENTAL
Intervention: National Children's Study Archive (NCSA) model
Number of subjects: 0
Study 33748052 — intervention group
Group type: EXPERIMENTAL
Intervention: NCSA model
Number of subjects: 0
Study 33748192 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel Restorative Pulmonary Valve Conduit
Number of subjects: 0
Study 33748192 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33748440 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (50 mg orally twice daily) starting 7 days prior to thoracic radiotherapy and continuing during radiotherapy (6-6.5 weeks; 60-66 Gy/30-33 fractions)
Number of subjects: 21
Study 33748660 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis Area Severity Index (PASI) score
Number of subjects: 0
Study 33748660 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in PASI score during 12 weeks of treatment
Number of subjects: 0
Study 33748660 — intervention group
Group type: EXPERIMENTAL
Intervention: Extent and change in PASI score
Number of subjects: 0
Study 33748842 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ACEi treatment
Number of subjects: 668
Study 33748842 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 668
Study 33748921 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab 600 mg fixed dose plus intravenous pertuzumab (loading dose: 840 mg/kg; maintenance: 420 mg/kg) and docetaxel (≥ 6 cycles; initial dose 75 mg/m2)
Number of subjects: 276
Study 33748921 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab plus intravenous pertuzumab and docetaxel
Number of subjects: 276
Study 33748997 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive periodontal care (SPC)
Number of subjects: 97
Study 33749049 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) 1,000 mg/m²
Number of subjects: 57
Study 33749049 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) + Melatonin
Number of subjects: 57
Study 33749049 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) + Metformin
Number of subjects: 57
Study 33749049 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) + Melatonin + Metformin
Number of subjects: 57
Study 33749502 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized colorectal cancer referral pathway (CCRP) introduced in September 2016
Number of subjects: 0
Study 33749502 — intervention group
Group type: COMPARATOR
Intervention: Routine colonoscopy
Number of subjects: 0
Study 33749608 — intervention group
Group type: EXPERIMENTAL
Intervention: mRehab system
Number of subjects: 11
Study 33749610 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced CDS alert informed by CDS best practices and PRISM IS framework
Number of subjects: 28
Study 33749610 — intervention group
Group type: COMPARATOR
Intervention: Commercial CDS alert
Number of subjects: 28
Study 33749611 — intervention group
Group type: EXPERIMENTAL
Intervention: Fun game-based moderate-to-vigorous physical activity (MVPA) training program (2 sessions/week, 60 minutes/session, for a total of 24 sessions)
Number of subjects: 48
Study 33749611 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (CG)
Number of subjects: 48
Study 33749611 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up testing scheduled 12 weeks after the intervention concludes
Number of subjects: 48
Study 33749611 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary outcomes (obesity- and fitness-related outcomes) and secondary outcome (blood pressure)
Number of subjects: 48
Study 33749616 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Based Exercise Therapy (HBET) using wearable technology and elastic band resistance exercises, 3 walking sessions and 2 resistance exercise sessions per week for 4 weeks.
Number of subjects: 20
Study 33749616 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Based Exercise Therapy (HBET)
Number of subjects: 20
Study 33749838 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg oral dose
Number of subjects: 24
Study 33750032 — intervention group
Group type: EXPERIMENTAL
Intervention: axSpA group
Number of subjects: 100
Study 33750032 — intervention group
Group type: COMPARATOR
Intervention: healthy volunteers (control group)
Number of subjects: 100
Study 33750072 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy
Number of subjects: 0
Study 33750072 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 33750196 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Number of subjects: 30
Study 33750196 — intervention group
Group type: COMPARATOR
Intervention: Last prior therapy
Number of subjects: 30
Study 33750210 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Expanding Transcatheter Aortic Valve
Number of subjects: 0
Study 33750210 — intervention group
Group type: COMPARATOR
Intervention: Balloon-Expandable Transcatheter Aortic Valve
Number of subjects: 0
Study 33750421 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance exercise (3 times per week for 4 weeks)
Number of subjects: 51
Study 33750421 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 51
Study 33750432 — intervention group
Group type: EXPERIMENTAL
Intervention: XAV-19 (polyclonal humanized anti-SARS-CoV2 antibodies) administered intravenously, dosage and duration not specified.
Number of subjects: 0
Study 33750432 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group), details not specified.
Number of subjects: 0
Study 33750454 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-initiated buprenorphine (BUP) with referral for treatment of OUD
Number of subjects: 3
Study 33750454 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation Facilitation (IF)
Number of subjects: 3
Study 33750925 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV-mediated gene delivery carrying the human CFI sequence
Number of subjects: 0
Study 33750925 — intervention group
Group type: EXPERIMENTAL
Intervention: Codon optimised constructs
Number of subjects: 0
Study 33750925 — intervention group
Group type: COMPARATOR
Intervention: Non-optimised CFI sequence
Number of subjects: 0
Study 33751029 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-defined remission
Number of subjects: 424
Study 33751029 — intervention group
Group type: EXPERIMENTAL
Intervention: Low disease activity (LDA)
Number of subjects: 424
Study 33751029 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of remission
Number of subjects: 424
Study 33751029 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal component analysis (PCA) for remission
Number of subjects: 424
Study 33751029 — intervention group
Group type: EXPERIMENTAL
Intervention: Key component for remission
Number of subjects: 424
Study 33751029 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors for LDA
Number of subjects: 424
Study 33751221 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM with mild cognitive impairment (T2MCI)
Number of subjects: 76
Study 33751221 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM without mild cognitive impairment (T2noMCI)
Number of subjects: 76
Study 33751221 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 76
Study 33751315 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV pre-exposure prophylaxis (PrEP)
Number of subjects: 200
Study 33751315 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 200
Study 33751315 — intervention group
Group type: EXPERIMENTAL
Intervention: Latinx ethnicity
Number of subjects: 200
Study 33751315 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 200
Study 33751355 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental responsiveness
Number of subjects: 241
Study 33751355 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental concern about adolescent weight
Number of subjects: 241
Study 33751355 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental responsibility for foods
Number of subjects: 241
Study 33751355 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental pressure-to-eat
Number of subjects: 241
Study 33751355 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental restriction
Number of subjects: 241
Study 33751421 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing of clinical C. difficile isolates
Number of subjects: 1501
Study 33752175 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeleton-assisted gait training
Number of subjects: 0
Study 33752251 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote intervention including three weekly phone calls and regular follow-up calls.
Number of subjects: 15
Study 33752251 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no specific intervention mentioned).
Number of subjects: 15
Study 33752405 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 250
Study 33752588 — intervention group
Group type: EXPERIMENTAL
Intervention: XYY probands
Number of subjects: 58
Study 33752588 — intervention group
Group type: COMPARATOR
Intervention: FSIQ and vocabulary scores
Number of subjects: 58
Study 33752659 — intervention group
Group type: EXPERIMENTAL
Intervention: Television off
Number of subjects: 200
Study 33752659 — intervention group
Group type: EXPERIMENTAL
Intervention: Children absent
Number of subjects: 200
Study 33752659 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging with a child
Number of subjects: 200
Study 33752659 — intervention group
Group type: EXPERIMENTAL
Intervention: Outside location
Number of subjects: 200
Study 33752659 — intervention group
Group type: EXPERIMENTAL
Intervention: Other adults absent
Number of subjects: 200
Study 33752659 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban mothers being outside
Number of subjects: 200
Study 33752659 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-urban mothers being outside
Number of subjects: 200
Study 33752659 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight mothers being outside
Number of subjects: 200
Study 33752659 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight/obese mothers being outside
Number of subjects: 200
Study 33752962 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin alone
Number of subjects: 3108
Study 33753433 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological testing for anti-hepatitis A virus, hepatitis B surface antigen, hepatitis B surface and core antibody
Number of subjects: 1327
Study 33753433 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire on attitudes towards viral hepatitis vaccination
Number of subjects: 1327
Study 33753437 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers associated with emphysema
Number of subjects: 463
Study 33753437 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging data (CT and magnetic resonance)
Number of subjects: 463
Study 33753437 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical parameters and medical events of special interest
Number of subjects: 463
Study 33753437 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety assessments
Number of subjects: 463
Study 33753457 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacritinib combined with Sirolimus and Low-Dose Tacrolimus (PAC/SIR/TAC)
Number of subjects: 0
Study 33753457 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacritinib (100 mg daily, 100 mg twice daily, 200 mg twice daily)
Number of subjects: 0
Study 33753457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual JAK2/mTOR inhibition
Number of subjects: 0
Study 33753460 — intervention group
Group type: EXPERIMENTAL
Intervention: Quarterly syndromic diagnosis and treatment for STI, HIV testing, peer-led counselling and support, provision of condoms and lubricants.
Number of subjects: 816
Study 33753864 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergence Insufficiency (CI)
Number of subjects: 100
Study 33753864 — intervention group
Group type: COMPARATOR
Intervention: Binocularly Normal Controls (BNC)
Number of subjects: 100
Study 33754103 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dartos TIP urethroplasty (Group A)
Number of subjects: 60
Study 33754103 — intervention group
Group type: COMPARATOR
Intervention: Double dartos TIP urethroplasty (Group B)
Number of subjects: 60
Study 33754144 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 6 mg/kg as a single intravenous infusion
Number of subjects: 40
Study 33754144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 33754187 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg with AAP
Number of subjects: 33
Study 33754187 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg with AAP
Number of subjects: 33
Study 33754187 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg with apalutamide
Number of subjects: 33
Study 33754187 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg
Number of subjects: 33
Study 33754187 — intervention group
Group type: COMPARATOR
Intervention: Niraparib 200 mg
Number of subjects: 33
Study 33754317 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline anticholinergic burden (ACB score ≥ 3)
Number of subjects: 19114
Study 33754317 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/highly anticholinergic medications
Number of subjects: 19114
Study 33754317 — intervention group
Group type: COMPARATOR
Intervention: Baseline anticholinergic burden (ACB score 1-2)
Number of subjects: 19114
Study 33754317 — intervention group
Group type: COMPARATOR
Intervention: Baseline anticholinergic burden (ACB score of zero)
Number of subjects: 19114
Study 33754642 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg)
Number of subjects: 37
Study 33754642 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (840 mg)
Number of subjects: 37
Study 33754642 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg and 840 mg)
Number of subjects: 37
Study 33754659 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-piece foldable IOL
Number of subjects: 54